Literature DB >> 32394283

A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.

Yeona Kang1,2, Sandra Milena Hurtado Rúa3, Ulrike W Kaunzner4, Jai Perumal4, Nancy Nealon4, Wenchao Qu1, Paresh J Kothari1, Timothy Vartanian4,5, Amy Kuceyeski1,5, Susan A Gauthier6,7,8.   

Abstract

PURPOSE: The γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter and essential for normal brain function. The GABAergic system has been shown to have immunomodulatory effects and respond adaptively to excitatory toxicity. The association of the GABAergic system and inflammation in patients with multiple sclerosis (MS) remains unknown. In this pilot study, the in vivo relationship between GABAA binding and the innate immune response is explored using positron emission tomography (PET) with [11C] flumazenil (FMZ) and [11C]-PK11195 PET (PK-PET), a measure of activated microglia/macrophages. PROCEDURES: Sixteen MS patients had dynamic FMZ-PET and PK-PET imaging. Ten age-matched healthy controls (HC) had a single FMZ-PET. GABAA receptor binding was calculated using Logan reference model with the pons as reference. Distribution of volume ratio (VTr) for PK-PET was calculated using image-derived input function. A hierarchical linear model was fitted to assess the linear association between PK-PET and FMZ-PET among six cortical regions of interest.
RESULTS: GABAA receptor binding was higher throughout the cortex in MS patients (5.72 ± 0.91) as compared with HC (4.70 ± 0.41) (p = 0.002). A significant correlation was found between FMZ binding and PK-PET within the cortex (r = 0.61, p < 0.001) and among the occipital (r = 0.61, p = 0.012), parietal (r = 0.49, p = 0.041), and cingulate (r = 0.32, p = 0.006) regions.
CONCLUSIONS: A higher GABAA receptor density in MS subjects compared with HC was observed and correlated with innate immune activity. Our observations demonstrate that immune-driven GABAergic abnormalities may be present in MS.

Entities:  

Keywords:  Flumazenil; GABAA receptor binding; Multiple sclerosis; Neuroinflammation; PK11195; Positron emission tomography

Mesh:

Substances:

Year:  2020        PMID: 32394283      PMCID: PMC8769531          DOI: 10.1007/s11307-020-01501-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  41 in total

1.  Graphical analysis of PET data applied to reversible and irreversible tracers.

Authors:  J Logan
Journal:  Nucl Med Biol       Date:  2000-10       Impact factor: 2.408

2.  Astrocytes are GABAergic cells that modulate microglial activity.

Authors:  Moonhee Lee; Claudia Schwab; Patrick L McGeer
Journal:  Glia       Date:  2011-01       Impact factor: 7.452

3.  Brainography: an atlas-independent surface and network rendering tool for neural connectivity visualization.

Authors:  E LoCastro; A Kuceyeski; A Raj
Journal:  Neuroinformatics       Date:  2014-04

4.  Cortical surface-based analysis. I. Segmentation and surface reconstruction.

Authors:  A M Dale; B Fischl; M I Sereno
Journal:  Neuroimage       Date:  1999-02       Impact factor: 6.556

5.  Interleukin-1beta enhances GABAA receptor cell-surface expression by a phosphatidylinositol 3-kinase/Akt pathway: relevance to sepsis-associated encephalopathy.

Authors:  Rocío Serantes; Francisco Arnalich; María Figueroa; Marta Salinas; Eva Andrés-Mateos; Rosa Codoceo; Jaime Renart; Carlos Matute; Carmen Cavada; Antonio Cuadrado; Carmen Montiel
Journal:  J Biol Chem       Date:  2006-03-27       Impact factor: 5.157

6.  [11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology.

Authors:  S Lamusuo; A Pitkänen; L Jutila; A Ylinen; K Partanen; R Kälviäinen; H M Ruottinen; V Oikonen; K Någren; P Lehikoinen; M Vapalahti; P Vainio; J O Rinne
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

7.  Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

Authors:  W Gordon Frankle; Raymond Y Cho; Rajesh Narendran; N Scott Mason; Shivangi Vora; Maralee Litschge; Julie C Price; David A Lewis; Chester A Mathis
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

8.  [18F]flumazenil binding to central benzodiazepine receptor studies by PET--quantitative analysis and comparisons with [11C]flumazenil.

Authors:  Ikuo Odano; Christer Halldin; Per Karlsson; Andrea Varrone; Anu J Airaksinen; Raisa N Krasikova; Lars Farde
Journal:  Neuroimage       Date:  2008-12-24       Impact factor: 6.556

9.  Validation of reference tissue modelling for [11C]flumazenil positron emission tomography following head injury.

Authors:  Thomas Geeraerts; Jonathan P Coles; Franklin I Aigbirhio; John D Pickard; David K Menon; Tim D Fryer; Young T Hong
Journal:  Ann Nucl Med       Date:  2011-04-02       Impact factor: 2.668

10.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

Authors:  R B Banati; J Newcombe; R N Gunn; A Cagnin; F Turkheimer; F Heppner; G Price; F Wegner; G Giovannoni; D H Miller; G D Perkin; T Smith; A K Hewson; G Bydder; G W Kreutzberg; T Jones; M L Cuzner; R Myers
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

View more
  4 in total

Review 1.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

2.  Longitudinal alterations in gamma-aminobutyric acid (GABAA) receptor availability over ∼ 1 year following traumatic brain injury.

Authors:  Y Kang; K Jamison; A Jaywant; K Dams-O'Connor; N Kim; N A Karakatsanis; T Butler; N D Schiff; A Kuceyeski; S A Shah
Journal:  Brain Commun       Date:  2022-06-15

Review 3.  Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Authors:  Aline M Thomas; Frederik Barkhof; Jeff W M Bulte
Journal:  Radiology       Date:  2022-04-26       Impact factor: 29.146

Review 4.  The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.

Authors:  Ido Ben-Shalom; Arnon Karni; Hadar Kolb
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.